Literature DB >> 35145015

Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention.

Stefan Teipel1,2, Deborah Gustafson3, Rik Ossenkoppele4,5, Oskar Hansson5, Claudio Babiloni6, Michael Wagner7,8, Steffi G Riedel-Heller9, Ingo Kilimann10,2, Yi Tang11.   

Abstract

Alzheimer disease (AD) is the most frequent cause of dementia in people 60 y old or older. This white paper summarizes the current standards of AD diagnosis, treatment, care, and prevention. Cerebrospinal fluid and PET measures of cerebral amyloidosis and tauopathy allow the diagnosis of AD even before dementia (prodromal stage) and provide endpoints for treatments aimed at slowing the AD course. Licensed pharmacologic symptomatic drugs enhance cholinergic pathways and moderate excess of glutamatergic transmission to stabilize cognition. Disease-modifying experimental drugs moderate or remove brain amyloidosis, but so far with modest clinical effects. Nonpharmacologic interventions and a healthy lifestyle (diet, socioaffective inclusion, cognitive stimulation, physical exercise, and others) provide some beneficial effects. Prevention targets mainly modifiable dementia risk factors such as unhealthy lifestyle, cardiovascular-metabolic and sleep-wake cycle abnormalities, and mental disorders. A major challenge for the future is telemonitoring in the real world of these modifiable risk factors.
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  PET; amyloid; biomarkers; dementia; prevention; treatment

Mesh:

Year:  2022        PMID: 35145015      PMCID: PMC9258577          DOI: 10.2967/jnumed.121.262239

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   11.082


  35 in total

Review 1.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

2.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings
Journal:  Lancet Neurol       Date:  2014-06       Impact factor: 44.182

Review 3.  A critical analysis of the 'amyloid cascade hypothesis'.

Authors:  R A Armstrong
Journal:  Folia Neuropathol       Date:  2014       Impact factor: 2.038

4.  Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.

Authors:  Leonardo Cruz de Souza; Foudil Lamari; Serge Belliard; Claude Jardel; Caroline Houillier; Raphael De Paz; Bruno Dubois; Marie Sarazin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-08-27       Impact factor: 10.154

5.  A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.

Authors:  Tiia Ngandu; Jenni Lehtisalo; Alina Solomon; Esko Levälahti; Satu Ahtiluoto; Riitta Antikainen; Lars Bäckman; Tuomo Hänninen; Antti Jula; Tiina Laatikainen; Jaana Lindström; Francesca Mangialasche; Teemu Paajanen; Satu Pajala; Markku Peltonen; Rainer Rauramaa; Anna Stigsdotter-Neely; Timo Strandberg; Jaakko Tuomilehto; Hilkka Soininen; Miia Kivipelto
Journal:  Lancet       Date:  2015-03-12       Impact factor: 79.321

6.  Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.

Authors:  Niklas Mattsson; Nicholas C Cullen; Ulf Andreasson; Henrik Zetterberg; Kaj Blennow
Journal:  JAMA Neurol       Date:  2019-07-01       Impact factor: 18.302

Review 7.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

8.  Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.

Authors:  Sebastian Palmqvist; Shorena Janelidze; Erik Stomrud; Henrik Zetterberg; Johann Karl; Katharina Zink; Tobias Bittner; Niklas Mattsson; Udo Eichenlaub; Kaj Blennow; Oskar Hansson
Journal:  JAMA Neurol       Date:  2019-09-01       Impact factor: 18.302

9.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.

Authors:  Suzanne E Schindler; James G Bollinger; Vitaliy Ovod; Kwasi G Mawuenyega; Yan Li; Brian A Gordon; David M Holtzman; John C Morris; Tammie L S Benzinger; Chengjie Xiong; Anne M Fagan; Randall J Bateman
Journal:  Neurology       Date:  2019-08-01       Impact factor: 11.800

10.  Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.

Authors:  Shorena Janelidze; Erik Stomrud; Ruben Smith; Sebastian Palmqvist; Niklas Mattsson; David C Airey; Nicholas K Proctor; Xiyun Chai; Sergey Shcherbinin; John R Sims; Gallen Triana-Baltzer; Clara Theunis; Randy Slemmon; Marc Mercken; Hartmuth Kolb; Jeffrey L Dage; Oskar Hansson
Journal:  Nat Commun       Date:  2020-04-03       Impact factor: 14.919

View more
  2 in total

1.  Shared genetic architecture between the two neurodegenerative diseases: Alzheimer's disease and glaucoma.

Authors:  Chunwen Zheng; Shunming Liu; Xiayin Zhang; Yunyan Hu; Xianwen Shang; Zhuoting Zhu; Yu Huang; Guanrong Wu; Yu Xiao; Zijing Du; Yingying Liang; Daiyu Chen; Siwen Zang; Yijun Hu; Mingguang He; Xueli Zhang; Honghua Yu
Journal:  Front Aging Neurosci       Date:  2022-09-01       Impact factor: 5.702

Review 2.  Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.

Authors:  Xavier Morató; Vanesa Pytel; Sara Jofresa; Agustín Ruiz; Mercè Boada
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.